Norepinephrine transporter −3081(A/T) and alpha-2A-adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS-methylphenidate treatment
Restricted accessResearch articleFirst published online March, 2012
Norepinephrine transporter −3081(A/T) and alpha-2A-adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS-methylphenidate treatment
The purpose of this study was to investigate a possible association between norepinephrine genes and cardiovascular side effects of the Osmotic Controlled-Release Oral Delivery System–methylphenidate (OROS-MPH) in Korean children with attention-deficit/hyperactivity disorder (ADHD). One hundred and one children with ADHD (8.7 ± 1.7 years) were recruited from child psychiatric centers at six university hospitals in South Korea. All participants were drug-naive ADHD children treated with OROS-MPH for 12 weeks. During the treatment period the investigators titrated the OROS-MPH dosage on the basis of symptom severity and side effects. Resting heart rate (HR), diastolic blood pressure (DBP), and systolic blood pressure (SBP) were examined before and after treatment. The percentage change score (post-treatment – pretreatment/pretreatment × 100) of each parameter was calculated. Genotyping of SLC6A2 −3081(A/T) and G1287A, and alpha-2A-adrenergic receptor (ADRA2A) MspI and DraI polymorphisms was performed. Clinically significant changes were not found in cardiovascular monitoring during the course of treatment. An increase of HR after OROS-MPH treatment was found to be statistically significant (t = 3.54, p = 0.001). Changes in SBP and DBP were not significant and no specific change was found in the ECGs. However, an additive regression analysis demonstrated a significant association between SLC6A2 −3081(A/T) and percentage change in HR post-treatment (p = 0.01) after controlling for age, gender, dosage of MPH and response and baseline pulse rate. Children with ADHD having the T/T genotype of SLC6A2 showed a 12.5% increase in HR compared to baseline, whereas children with the A/T or A/A genotype showed a 3.5% and 2.5% increase after OROS-MPH treatment, respectively. There was also a significant association between the ADRA2A MspI genotype and percentage change of DBP post-treatment after controlling for age, gender, dosage of MPH and response and baseline DBP (p = 0.009). Children with ADHD having the C/C genotype of ADRA2A MspI showed an 18.5% increase in DBP compared to baseline, but children with the G/G or G/C genotype showed a 0.2% decrease after OROS-MPH treatment. The overall cardiovascular effects of OROS-MPH were modest. However, our findings show a positive association between norepinephrine-related gene polymorphisms and cardiovascular response induced by MPH in Korean children with ADHD. Consideration must be given to such children oradults with specific norepinephrine-related genotypes, especially if they show significant changes in HR or DBP after OROS-MPH administration.
AbikoffHBVitielloBRiddleMA. (2007) Methylphenidate effects on functional outcomes in the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). J Child Adolesc Psychopharmacol17: 581–592.
2.
AdlerLAZimmermanBStarrHL. (2009) Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study. J Clin Psychopharmacol29: 239–247.
3.
Akaike (1974) A new look at the statistical model identification. IEEE Transactions on Automatic Control, 19(6): 716–723.
4.
AndrewsGDLavinA (2006) Methylphenidate increases cortical excitability via activation of alpha-2 noradrenergic receptors. Neuropsychopharmacology31: 594–601.
5.
Anon (1999) A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry56: 1073–1086.
6.
Anon (2004) National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. Pediatrics113: 754–761.
7.
AssociationAP (2000) Diagnostic and Statistical Manual of Mental Disorders, 4th ed.Washington, DC: American Psychiatric Association text revision.
8.
BerridgeCWDevilbissDMAndrzejewskiME. (2006) Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biol Psychiatry60: 1111–1120.
9.
BirkenfeldALSchroederCBoschmannM. (2002) Paradoxical effect of sibutramine on autonomic cardiovascular regulation. Circulation106: 2459–2465.
10.
BonoMCasesAOriolaJ. (1996) Polymorphisms of the human alpha 2A-adrenergic receptor gene in a Catalan population: description of a new polymorphism in the promoter region. Gene Geogr10: 151–159.
11.
CarsonRPDiedrichARobertsonD (2002) Autonomic control after blockade of the norepinephrine transporter: a model of orthostatic intolerance. J Appl Physiol93: 2192–2198.
12.
CheonKAChoDYKooMS. (2009) Association between homozygosity of a G allele of the alpha-2a-adrenergic receptor gene and methylphenidate response in Korean children and adolescents with attention-deficit/hyperactivity disorder. Biol Psychiatry65: 564–570.
13.
ChoSCKimJWKimBN. (2008) Possible association of the alpha-2A-adrenergic receptor gene with response time variability in attention deficit hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet147B: 957–963.
14.
da SilvaTLPiancaTGRomanT. (2008) Adrenergic alpha2A receptor gene and response to methylphenidate in attention-deficit/hyperactivity disorder-predominantly inattentive type. JNeural Transm115: 341–345.
15.
DaviesSLowryCANuttDJ (2007) Panic and hypertension: brothers in arms through 5-HT?J Psychopharmacology21: 563–566.
16.
DuPaulGJ (1991) Parent and teacher ratings of ADHD symptoms: psychometric properties in a community-based sample. J Clin Child Psychol20: 245–253.
17.
FindlingRLShortEJManosMJ (2001) Short-term cardiovascular effects of methylphenidate and adderall. J Am Acad Child Adolesc Psychiatry40: 525–529.
18.
FroehlichTEMcGoughJJSteinMA (2010) Progress and promise of attention-deficit hyperactivity disorder pharmacogenetics. CNS Drugs24: 99–117.
19.
GhumanJKAmanMGLecavalierL. (2009) Randomized, placebo-controlled, crossover study of methylphenidate for attention-deficit/hyperactivity disorder symptoms in preschoolers with developmental disorders. J Child Adolesc Psychopharmacol19: 329–339.
20.
GouldMSWalshBTMunfakhJLKleinmanMDuanNOlfsonM. (2009) Sudden death and use of stimulant medications in youths. Am J Psychiatry166: 992–1001.
21.
GruberRJooberRGrizenkoN. (2009) Dopamine transporter genotype and stimulant side effect factors in youth diagnosed withattention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol19: 233–239.
22.
GutgesellHAtkinsDBarstR. (1999) AHA Scientific Statement: cardiovascular monitoring of children and adolescents receiving psychotropic drugs. J Am Acad Child Adolesc Psychiatry38: 1047–1050.
23.
HammernessPWilensTMickE. (2009) Cardiovascular effects of longer-term, high-dose OROS methylphenidate in adolescents with attention deficit hyperactivity disorder. J Pediatr155: 84–89, 89e81.
24.
KarahalilBCoskunEEmerceE (2008) ADRA2A polymorphism and smoking in a Turkish population. Toxicol Ind Health24: 171–176.
25.
KaufmanJBBBrentDRaoUFlynnCMoreciP (1997) Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Life Time Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry36: 980–988.
26.
KebirOTabbaneKSenguptaS. (2009) Candidate genes and neuropsychological phenotypes in children with ADHD: review of association studies. J Psychiatry Neurosci34: 88–101.
27.
KellerNRDiedrichAAppalsamyM. (2004) Norepinephrine transporter-deficient mice exhibit excessive tachycardia and elevated blood pressure with wakefulness and activity. Circulation110: 1191–1196.
28.
KimCHHMJoungYAndersonSL. (2006) A polymorphism in the norepinephrine transporter gene alters promoter activity and is associated with attention-deficit hyperactivity disorder. Proc Natl Acad Sci USA103: 19164–19169.
29.
KimYSCKKimBNChangSAYooHJKimJW (2004) The reliability and validity of Kiddie-Schedule for Affective Disorders and Schizophrenia - Present and Lifetime Version – Korean Version (K-SADS-PL-K). Yonsei Med J45: 81–89.
30.
KobelMBechtelNWeberP. (2009) Effects of methylphenidate on working memory functioning in children with attention deficit/hyperactivity disorder. Eur J Paediatr Neurol13: 516–523.
31.
KurnikDMuszkatMLiC. (2006) Variations in the alpha2A-adrenergic receptor gene and their functional effects. Clin Pharmacol Ther79: 173–185.
32.
LarioSCallsJCasesA. (1997) MspI identifies a biallelic polymorphism in the promoter region of the alpha 2A-adrenergic receptor gene. Clin Genet51: 129–130.
33.
LeddyJJWaxmonskyJGSalisRJ. (2009) Dopamine-related genotypes and the dose-response effect of methylphenidate on eating in attention-deficit/hyperactivity disorder youths. J Child Adolesc Psychopharmacol19: 127–136.
34.
MayerAFSchroederCHeusserK. (2006) Influences of norepinephrine transporter function on the distribution of sympathetic activity in humans. Hypertension48: 120–126.
35.
McCafferyJMPogue-GeileMFFerrellRE. (2002) Variability within alpha- and beta-adrenoreceptor genes as a predictor of cardiovascular function at rest and in response to mental challenge. J Hypertens20: 1105–1114.
36.
McGoughJMcCrackenJSwansonJ. (2006) Pharmacogenetics of methylphenidate response in preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry45: 1314–1322.
37.
National Institute of Mental Health (1970) CGI, Clinical Global Impressions. In: GuyWBR (ed) Manual of the ECDEU Assessment Battery, revised edition. Maryland: NIMH.
38.
NegraoBLCraffordDViljoenM (2009) The effect of sympathomimetic medication on cardiovascular functioning of children with attention-deficit/hyperactivity disorder. Cardiovasc J Afr20: 296–299.
39.
PliszkaS (2007) Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry46: 894–921.
40.
PolanczykGZeniCGenroJP. (2007) Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry64: 218–224.
41.
Ramos-QuirogaJACorominasMCastellsX. (2009) OROS methylphenidate for the treatment of adults with attention-deficit/hyperactivity disorder. Expert Rev Neurother9: 1121–1131.
42.
RosmondRBouchardCBjorntorpP (2002) A C-1291G polymorphism in the alpha2A-adrenergic receptor gene (ADRA2A) promoter is associated with cortisol escape from dexamethasone and elevated glucose levels. J Intern Med251: 252–257.
43.
RubiaKHalariRChristakouA. (2009a) Impulsiveness as a timing disturbance: neurocognitive abnormalities in attention-deficit hyperactivity disorder during temporal processes and normalization with methylphenidate. Philos Trans R Soc Lond B Biol Sci364: 1919–1931.
44.
RubiaKHalariRCubilloA. (2009b) Methylphenidate normalises activation and functional connectivity deficits in attention and motivation networks in medication-naive children with ADHD during a rewarded continuous performance task. Neuropharmacology57: 640–652.
45.
SaferDJ (1992) Relative cardiovascular safety of psychostimulants used to treat attention-deficit hyperactivity disorder. J Child Adolesc Psychopharmacol2: 279–290.
46.
SchroederCAdamsFBoschmannM. (2004) Phenotypical evidence for a gender difference in cardiac norepinephrine transporter function. Am J Physiol Regul Integr Comp Physiol286: R851–856.
47.
ShannonJRFlattemNLJordanJ. (2000) Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency. N Engl J Med342: 541–549.
48.
ShibaoCRajSRGamboaA. (2007) Norepinephrine transporter blockade with atomoxetine induces hypertension in patients with impaired autonomic function. Hypertension50: 47–53.
49.
SoYKNJKimYSKoSGKohSJ (2002) The reliability and validity of Korean parent and teacher ADHD Rating Scale. J Korean Neuropsychiatr Assoc41: 283–289.
50.
SoberSOrgEKeppK. (2009) Targeting 160 candidate genes for blood pressure regulation with a genome-wide genotyping array. PLoS One4: e6034.
51.
SolantoMV (1998) Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res94: 127–152.
52.
StrempelSSchroederCHemmersbachR. (2008) Norepinephrine transporter inhibition alters the hemodynamic response to hypergravitation. J Appl Physiol104: 756–760.
53.
SungYSCS (1995) The standardization of Korean CGI-I and CGI-S in children. Proceedings of Annual Meeting of Korean Neuropsychiatric Association.
54.
TankJSchroederCDiedrichA. (2003) Selective impairment in sympathetic vasomotor control with norepinephrine transporter inhibition. Circulation107: 2949–2954.
55.
ThompsonJThompsonJR (2010) Acute myocardial infarction related to methylphenidate for adult attention deficit disorder. J Emerg Med38: 18–21.
56.
VolkowNDWangGJFowlerJS. (2003) Cardiovascular effects of methylphenidate in humans are associated with increases of dopamine in brain and of epinephrine in plasma. Psychopharmacology (Berl)166: 264–270.
57.
WakamatsuANomuraSTateY. (2009) Effects of methylphenidate hydrochloride on the cardiovascular system in vivo and in vitro: a safety pharmacology study. J Pharmacol Toxicol Methods59: 128–134.
58.
WangYZhengYDuY. (2007) Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial. Aust N Z J Psychiatry41: 222–230.
59.
WilensTEHammernessPGBiedermanJ. (2005) Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry66: 253–259.
60.
WintersteinAGGerhardTShusterJ. (2009) Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD. Pediatrics124: e75–80.
61.
Xavier SoleEGVallsJIniestaRMorenoV (2006) SNPstats. Biostatistics and Bioinformatics Unit at Catalan Institute of Oncology.
62.
YangLWYLiJFaraoneSV (2004) Association of norepinephrine transporter gene with methylphenidate response. J Am Acad Child Adolesc Psychiatry43: 1154–1158.
